ARTICLE | Clinical News
NicOx's HCT-3012 in Phase II
January 24, 2001 8:00 AM UTC
NicOx (NM:Nicox) said that partner AntraZeneca (AZN) began Phase II testing of Nicox's HCT 3012 nitric oxide non-steroidal anti-inflammatory (NO-NSAID), triggering a $3 million payment to Nicox. The U...